APOBEC proteins and intrinsic resistance to HIV-1 infection
暂无分享,去创建一个
[1] B. Cullen,et al. Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. , 2008, RNA.
[2] B. Cullen,et al. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. , 2005, Virology.
[3] T. Rana,et al. Human Retroviral Host Restriction Factors APOBEC3G and APOBEC3F Localize to mRNA Processing Bodies , 2006, PLoS pathogens.
[4] M. Malim,et al. Hypermutation of an Ancient Human Retrovirus by APOBEC3G , 2008, Journal of Virology.
[5] W. J. Esselman,et al. Identification of APOBEC3DE as Another Antiretroviral Factor from the Human APOBEC Family , 2006, Journal of Virology.
[6] Nelson L Michael,et al. Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. , 2008, Virology.
[7] S. Heath,et al. Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. , 2005, The Journal of infectious diseases.
[8] V. Pathak,et al. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[9] R. König,et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome , 2004, Nature Structural &Molecular Biology.
[10] B. Strack,et al. Vif Overcomes the Innate Antiviral Activity of APOBEC3G by Promoting Its Degradation in the Ubiquitin-Proteasome Pathway* , 2004, Journal of Biological Chemistry.
[11] M. Malim,et al. Antiviral Potency of APOBEC Proteins Does Not Correlate with Cytidine Deamination , 2006, Journal of Virology.
[12] V. Pathak,et al. Identification of Two Distinct Human Immunodeficiency Virus Type 1 Vif Determinants Critical for Interactions with Human APOBEC3G and APOBEC3F , 2007, Journal of Virology.
[13] K. Iwai,et al. Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C Complex Is Essential for Vif Function* , 2005, Journal of Biological Chemistry.
[14] J. Coffin,et al. Role of APOBEC3 in Genetic Diversity among Endogenous Murine Leukemia Viruses , 2007, PLoS genetics.
[15] L. Montagnier,et al. HIV/HTLV gene nomenclature , 1988, Nature.
[16] W. Greene,et al. Newly Synthesized APOBEC3G Is Incorporated into HIV Virions, Inhibited by HIV RNA, and Subsequently Activated by RNase H , 2007, PLoS pathogens.
[17] Robert F. Siliciano,et al. Role of APOBEC3G/F-Mediated Hypermutation in the Control of Human Immunodeficiency Virus Type 1 in Elite Suppressors , 2007, Journal of Virology.
[18] D. Pérez-Caballero,et al. APOBEC3G Incorporation into Human Immunodeficiency Virus Type 1 Particles , 2004, Journal of Virology.
[19] F. McCutchan,et al. Human Immunodeficiency Virus Type 1 DNA Sequences Genetically Damaged by Hypermutation Are Often Abundant in Patient Peripheral Blood Mononuclear Cells and May Be Generated during Near-Simultaneous Infection and Activation of CD4+ T Cells , 2001, Journal of Virology.
[20] R. Wolfenden,et al. Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex. , 1994, Journal of molecular biology.
[21] Robert M Grant,et al. Target Cell APOBEC3C Can Induce Limited G-to-A Mutation in HIV-1 , 2007, PLoS pathogens.
[22] M. Malim,et al. The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross‐species transmission , 1998, The EMBO journal.
[23] Xianghui Yu,et al. Induction of APOBEC 3 G Ubiquitination and Degradation by an HIV-1 Vif-Cul 5-SCF Complex , 2022 .
[24] Reuben S. Harris,et al. Retroviral restriction by APOBEC proteins , 2004, Nature Reviews Immunology.
[25] M. Neuberger,et al. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. , 2005, Molecular biology and evolution.
[26] M. Marin,et al. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation , 2003, Nature Medicine.
[27] D. Trono,et al. A Single Amino Acid Determinant Governs the Species-specific Sensitivity of APOBEC3G to Vif Action* , 2004, Journal of Biological Chemistry.
[28] J. Goncalves,et al. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. , 2004, Genes & development.
[29] G. Heidecker,et al. Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid , 2007, Proceedings of the National Academy of Sciences.
[30] Michael Emerman,et al. HIV-1 accessory proteins--ensuring viral survival in a hostile environment. , 2008, Cell host & microbe.
[31] D. Trono,et al. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells , 1993, Journal of virology.
[32] R. Reichman,et al. APOBEC3G/CEM15 (hA3G) mRNA Levels Associate Inversely with Human Immunodeficiency Virus Viremia , 2005, Journal of Virology.
[33] W. Brown,et al. APOBEC3F Properties and Hypermutation Preferences Indicate Activity against HIV-1 In Vivo , 2004, Current Biology.
[34] P. Bieniasz,et al. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. , 2006, Virology.
[35] P. Munson,et al. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. , 2007, Blood.
[36] M. Khan,et al. Human Immunodeficiency Virus Type 1 Vif Inhibits Packaging and Antiviral Activity of a Degradation-Resistant APOBEC3G Variant , 2007, Journal of Virology.
[37] T. Hope,et al. APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells. , 2008, Virology.
[38] M. Marin,et al. The Anti-HIV-1 Editing Enzyme APOBEC3G Binds HIV-1 RNA and Messenger RNAs That Shuttle between Polysomes and Stress Granules* , 2006, Journal of Biological Chemistry.
[39] P. Spearman,et al. APOBEC3G Multimers Are Recruited to the Plasma Membrane for Packaging into Human Immunodeficiency Virus Type 1 Virus-Like Particles in an RNA-Dependent Process Requiring the NC Basic Linker , 2007, Journal of Virology.
[40] R. Desrosiers,et al. Identification of Highly Attenuated Mutants of Simian Immunodeficiency Virus , 1998, Journal of Virology.
[41] M. Klein,et al. The APOBEC-2 crystal structure and functional implications for the deaminase AID , 2007, Nature.
[42] W. Kaelin,et al. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.
[43] Shu Zheng,et al. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[44] M. Malim,et al. Identification of Amino Acid Residues in APOBEC3G Required for Regulation by Human Immunodeficiency Virus Type 1 Vif and Virion Encapsidation , 2007, Journal of Virology.
[45] Hui Li,et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.
[46] V. Andrésdóttir,et al. Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins , 2006, Nucleic acids research.
[47] M. Malim,et al. Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins , 1996, Journal of virology.
[48] R. König,et al. Species-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif , 2003, Cell.
[49] P. Bieniasz,et al. Generation of Simian-Tropic HIV-1 by Restriction Factor Evasion , 2006, Science.
[50] Ma Luo,et al. Human Immunodeficiency Virus (HIV) Type 1 Proviral Hypermutation Correlates with CD4 Count in HIV-Infected Women from Kenya , 2008, Journal of Virology.
[51] L. Lopalco,et al. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. , 2007, The Journal of infectious diseases.
[52] M. Malim,et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.
[53] W. Greene,et al. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. , 2003, Molecular cell.
[54] S. Calattini,et al. Restriction of Foamy Viruses by APOBEC Cytidine Deaminases , 2006, Journal of Virology.
[55] M Sala,et al. G-->A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[56] Xiao-Fang Yu,et al. Regulation of Apobec3F and Human Immunodeficiency Virus Type 1 Vif by Vif-Cul5-ElonB/C E3 Ubiquitin Ligase , 2005, Journal of Virology.
[57] M. Malim,et al. DNA Deamination Mediates Innate Immunity to Retroviral Infection , 2003, Cell.
[58] Reuben S Harris,et al. The Vif Protein of HIV Triggers Degradation of the Human Antiretroviral DNA Deaminase APOBEC3G , 2003, Current Biology.
[59] Yong-Hui Zheng,et al. APOBEC3G Is Degraded by the Proteasomal Pathway in a Vif-dependent Manner without Being Polyubiquitylated* , 2008, Journal of Biological Chemistry.
[60] R. König,et al. Complementary function of the two catalytic domains of APOBEC3G. , 2005, Virology.
[61] W. Greene,et al. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition , 2006, Proceedings of the National Academy of Sciences.
[62] M. Khan,et al. Viral RNA Is Required for the Association of APOBEC3G with Human Immunodeficiency Virus Type 1 Nucleoprotein Complexes , 2005, Journal of Virology.
[63] B. Cullen,et al. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. , 2004, Virology.
[64] J. Goedert,et al. Polymorphisms of CUL5 Are Associated with CD4+ T Cell Loss in HIV-1 Infected Individuals , 2007, PLoS genetics.
[65] W. Greene,et al. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells , 2005, Nature.
[66] M. Malim,et al. Evidence for a newly discovered cellular anti-HIV-1 phenotype , 1998, Nature Medicine.
[67] M. Malim,et al. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes , 1996, Journal of virology.
[68] M. Goodman,et al. APOBEC3G DNA deaminase acts processively 3′ → 5′ on single-stranded DNA , 2006, Nature Structural &Molecular Biology.
[69] A. Engelman,et al. Human Immunodeficiency Virus Type 1 cDNAs Produced in the Presence of APOBEC3G Exhibit Defects in Plus-Strand DNA Transfer and Integration , 2007, Journal of Virology.
[70] C. Burant,et al. Molecular cloning of an apolipoprotein B messenger RNA editing protein. , 1993, Science.
[71] B. Cullen,et al. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV‐1 and HIV‐2 Vif proteins , 2004, The EMBO journal.
[72] Gersende Caron,et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts , 2003, Nature.
[73] Amalio Telenti,et al. APOBEC3G Genetic Variants and Their Influence on the Progression to AIDS , 2004, Journal of Virology.
[74] J. Church. Identification of Host Proteins Required for HIV Infection Through a Functional Genomic Screen , 2008, Pediatrics.
[75] M. Neuberger,et al. Human APOBEC3G Can Restrict Retroviral Infection in Avian Cells and Acts Independently of both UNG and SMUG1 , 2008, Journal of Virology.
[76] Michel Henry,et al. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. , 2004, Nucleic acids research.
[77] P. Sova,et al. Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1 , 1993, Journal of virology.
[78] M. Stevenson,et al. HIV‐1 replication is controlled at the level of T cell activation and proviral integration. , 1990, The EMBO journal.
[79] A. Fisher,et al. The sor gene of HIV-1 is required for efficient virus transmission in vitro. , 1987, Science.
[80] T. Heidmann,et al. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses , 2005, Nature.
[81] B. Cullen,et al. The Betaretrovirus Mason-Pfizer Monkey Virus Selectively Excludes Simian APOBEC3G from Virion Particles , 2006, Journal of Virology.
[82] M. Malim,et al. Cytidine Deamination of Retroviral DNA by Diverse APOBEC Proteins , 2004, Current Biology.
[83] S. Anant,et al. Molecular mechanisms of apolipoprotein B mRNA editing , 2001, Current opinion in lipidology.
[84] M. Emerman,et al. Uracil DNA Glycosylase Is Dispensable for Human Immunodeficiency Virus Type 1 Replication and Does Not Contribute to the Antiviral Effects of the Cytidine Deaminase Apobec3G , 2006, Journal of Virology.
[85] Tara L. Kieffer,et al. G→A Hypermutation in Protease and Reverse Transcriptase Regions of Human Immunodeficiency Virus Type 1 Residing in Resting CD4+ T Cells In Vivo , 2005, Journal of Virology.
[86] S. Wain-Hobson,et al. Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication , 2006, Nucleic acids research.
[87] H. Hanenberg,et al. Restriction of Foamy Viruses by Primate Trim5α , 2008, Journal of Virology.
[88] Yunkai Yu,et al. Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex , 2003, Science.
[89] H. Matsuo,et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G , 2008, Nature.
[90] M. Malim,et al. APOBEC-Mediated Editing of Viral RNA , 2004, Science.
[91] C. Lilley,et al. APOBEC3A Is a Potent Inhibitor of Adeno-Associated Virus and Retrotransposons , 2006, Current Biology.
[92] A. Telenti,et al. Model Structure of Human APOBEC3G , 2007, PloS one.
[93] M. Malim,et al. Antiviral Function of APOBEC3G Can Be Dissociated from Cytidine Deaminase Activity , 2005, Current Biology.
[94] Jerome A. Zack,et al. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure , 1990, Cell.
[95] J. Kappes,et al. Cytidine Deaminases APOBEC3G and APOBEC3F Interact with Human Immunodeficiency Virus Type 1 Integrase and Inhibit Proviral DNA Formation , 2007, Journal of Virology.
[96] R. Harris,et al. The DNA Deaminase Activity of Human APOBEC3G Is Required for Ty1, MusD, and Human Immunodeficiency Virus Type 1 Restriction , 2008, Journal of Virology.
[97] M. Malim,et al. DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses , 2003, Nature Immunology.
[98] J. Sodroski,et al. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes , 1992, Journal of virology.
[99] E. Thomas,et al. A Zinc-binding Region in Vif Binds Cul5 and Determines Cullin Selection* , 2006, Journal of Biological Chemistry.
[100] D. Ho,et al. Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification , 2005, PLoS pathogens.
[101] Hui Zhang,et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA , 2003, Nature.
[102] S. Goff. Genetic control of retrovirus susceptibility in mammalian cells. , 2004, Annual review of genetics.
[103] B. Cullen,et al. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[104] K. Metzner,et al. Comparison of G-to-A Mutation Frequencies Induced by APOBEC3 Proteins in H9 Cells and Peripheral Blood Mononuclear Cells in the Context of Impaired Processivities of Drug-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptase Variants , 2008, Journal of Virology.
[105] Xianghui Yu,et al. Differential Requirement for Conserved Tryptophans in Human Immunodeficiency Virus Type 1 Vif for the Selective Suppression of APOBEC3G and APOBEC3F , 2006, Journal of Virology.
[106] M. Malim,et al. SnapShot: HIV-1 Proteins , 2008, Cell.
[107] M. Malim,et al. APOBEC3F Can Inhibit the Accumulation of HIV-1 Reverse Transcription Products in the Absence of Hypermutation , 2007, Journal of Biological Chemistry.
[108] M. Malim,et al. APOBEC-mediated viral restriction: not simply editing? , 2007, Trends in biochemical sciences.
[109] B. Cullen,et al. The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. , 2007, Virology.
[110] P. T. N. Sarkis,et al. 7SL RNA Mediates Virion Packaging of the Antiviral Cytidine Deaminase APOBEC3G , 2007, Journal of Virology.
[111] S. Wain-Hobson,et al. Evidence for Editing of Human Papillomavirus DNA by APOBEC3 in Benign and Precancerous Lesions , 2008, Science.
[112] M. Malim,et al. Antiviral Protein APOBEC3G Localizes to Ribonucleoprotein Complexes Found in P Bodies and Stress Granules , 2006, Journal of Virology.
[113] L. Kleiman,et al. Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. , 2006, Journal of virology.
[114] M. Malim,et al. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif , 2003, Nature Medicine.
[115] 村松 正道. Specific expression of activation-induced cytidine deaminase (AID) , a novel member of the RNA editing deaminase family in germinal center B cells , 1999 .
[116] J. Lieberman,et al. Identification of Host Proteins Required for HIV Infection Through a Functional Genomic Screen , 2007, Science.
[117] Navid Madani,et al. An Endogenous Inhibitor of Human Immunodeficiency Virus in Human Lymphocytes Is Overcome by the Viral Vif Protein , 1998, Journal of Virology.
[118] G. Manning,et al. Mutational Alteration of Human Immunodeficiency Virus Type 1 Vif Allows for Functional Interaction with Nonhuman Primate APOBEC3G , 2006, Journal of Virology.
[119] W. Greene,et al. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. , 2008, Annual review of immunology.
[120] N. Landau,et al. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[121] M. Malim,et al. Further Investigation of Simian Immunodeficiency Virus Vif Function in Human Cells , 2004, Journal of Virology.
[122] M. Malim,et al. APOBEC3G Inhibits Elongation of HIV-1 Reverse Transcripts , 2008, PLoS pathogens.
[123] K. Strebel,et al. The HIV A (sor) gene product is essential for virus infectivity , 1987, Nature.
[124] Xianghui Yu,et al. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. , 2004, Genes & development.
[125] P. Bieniasz. Intrinsic immunity: a front-line defense against viral attack , 2004, Nature Immunology.
[126] B. Chang,et al. Apolipoprotein Β mRNA Editing , 1998 .
[127] M. Neuberger,et al. Molecular mechanisms of antibody somatic hypermutation. , 2007, Annual review of biochemistry.
[128] D. Palmer,et al. Human immunodeficiency virus. , 1990, Journal of the American Podiatric Medical Association.
[129] J. Fitzgibbon,et al. A new type of G-->A hypermutation affecting human immunodeficiency virus. , 1993, AIDS research and human retroviruses.
[130] M. Khan,et al. Enzymatically Active APOBEC3G Is Required for Efficient Inhibition of Human Immunodeficiency Virus Type 1 , 2007, Journal of Virology.
[131] F. Rey,et al. Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps , 1995, Journal of virology.
[132] V. Pathak,et al. Human Apolipoprotein B mRNA-editing Enzyme-catalytic Polypeptide-like 3G (APOBEC3G) Is Incorporated into HIV-1 Virions through Interactions with Viral and Nonviral RNAs* , 2004, Journal of Biological Chemistry.
[133] Takeshi Kurosu,et al. Human APOBEC3F Is Another Host Factor That Blocks Human Immunodeficiency Virus Type 1 Replication , 2004, Journal of Virology.
[134] Reuben S Harris,et al. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. , 2002, Molecular cell.
[135] A. Gronenborn,et al. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G , 2007, Nucleic acids research.
[136] M. Malim,et al. Comprehensive Investigation of the Molecular Defect in vif-Deficient Human Immunodeficiency Virus Type 1 Virions , 2003, Journal of Virology.
[137] H. Takeuchi,et al. Biochemical Activities of Highly Purified, Catalytically Active Human APOBEC3G: Correlation with Antiviral Effect , 2006, Journal of Virology.
[138] N. Davidson,et al. APOBEC3F and APOBEC3G mRNA Levels Do Not Correlate with Human Immunodeficiency Virus Type 1 Plasma Viremia or CD4+ T-Cell Count , 2006, Journal of Virology.
[139] Xianghui Yu,et al. Amino-Terminal Region of the Human Immunodeficiency Virus Type 1 Nucleocapsid Is Required for Human APOBEC3G Packaging , 2004, Journal of Virology.
[140] M. Gonda,et al. Conservation of amino-acid sequence motifs in lentivirus Vif proteins , 2005, Virus Genes.
[141] Lorne W. Walker,et al. T Cells Contain an RNase-Insensitive Inhibitor of APOBEC3G Deaminase Activity , 2007, PLoS pathogens.